References
- Feldmann H, Feldmann F, Marzi A. Ebola: lessons on vaccine development. Annu Rev Microbiol. 2018;72:423–446.
- Fineberg HV. Pandemic Preparedness and response — lessons from the H1N1 influenza of 2009. N Engl J Med. 2014;370(14):1335–1342.
- U.S. Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. cited 2023 Feb 6. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19
- U.S. Food and Drug Administration. Emergency use authorization for vaccines to prevent COVID-19. cited 2023 Feb 6. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-vaccines-prevent-covid-19
- D’Alò GL, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization. J Prev Med Hyg. 2017;58:E13–E26.
- Durand J, Dogné JM, Cohet C, et al. Safety monitoring of COVID-19 vaccines: perspective from the European medicines agency. Clin Pharmacol Ther. 2022 Dec:16. DOI:10.1002/cpt.2828
- Cocoros NM, Fuller CC, Adimadhyam S, et al. A COVID-19-ready public health surveillance system: the food and drug Administration’s sentinel system. Pharmacoepidemiol Drug Saf. 2021;30(7):827–883.
- U.S. Food and Drug Administration. CBER biologics effectiveness and safety (BEST) system. cited 2023 Feb 6. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-biologics-effectiveness-and-safety-best-system
- Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the world allergy organization anaphylaxis committee. World Allergy Organ J. 2021;14:100517.
- Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471–484.
- Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58–61.
- Cohn B, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. JAMA. 2021;375:331–336.
- Marks PW, Gruppuso PA, Adashi EY. Urgent need for next generation COVID-19 vaccines. JAMA. 2022 Dec 9;329(1):19–20.
- U.S. Food and Drug Administration. Moderna decision memorandum (August 31, 2022) and pfizer decision memorandum (August 21, 2022). cited 2023 Feb 6. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
- Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection - increasing community access to testing program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1526–1530.